Clinical Trial of Imfinzi (Durvalumab) in Conjunction with Chemotherapy Yields Significantly Longer Survival Time for Patients Diagnosed with Malignant Pleural Mesothelioma

Immuno-Oncology News recently published results of a Phase 2 clinical trial of the immuno-checkpoint inhibitor Imfinzi (durvalumab) for patients diagnosed with malignant pleural mesothelioma.  The PrECOG cancer research group tested the effects of pairing Imfinzi, an AstraZeneca drug that blocks the activity of the PD-1 receptor in immune T-cells, with standard chemotherapy on a group of 55 individuals who had been recently diagnosed with inoperable malignant pleural mesothelioma. The PD-1/PD-L1 pathway affects inflammation, which causes pleural mesothelioma to develop at a faster rate. The trial revealed that patients who took Imfinzi in addition to running out courses of standard chemotherapy […]

The post Clinical Trial of Imfinzi (Durvalumab) in Conjunction with Chemotherapy Yields Significantly Longer Survival Time for Patients Diagnosed with Malignant Pleural Mesothelioma appeared first on Mesothelioma Help Cancer Organization.

from Blog – Mesothelioma Help Cancer Organization https://ift.tt/30YHE8b
via IFTTT